Abstract
Glucose transporters (GLUTs) at the blood-brain barrier maintain the continuous high glucose and energy demands of the brain. They also act as therapeutic targets and provide routes of entry for drug delivery to the brain and central nervous system for treatment of neurological and neurovascular conditions and brain tumours. This article first describes the distribution, function and regulation of glucose transporters at the blood-brain barrier, the major ones being the sodium-independent facilitative transporters GLUT1 and GLUT3. Other GLUTs and sodium-dependent transporters (SGLTs) have also been identified at lower levels and under various physiological conditions. It then considers the effects on glucose transporter expression and distribution of hypoglycemia and hyperglycemia associated with diabetes and oxygen/glucose deprivation associated with cerebral ischemia. A reduction in glucose transporters at the blood-brain barrier that occurs before the onset of the main pathophysiological changes and symptoms of Alzheimer’s disease is a potential causative effect in the vascular hypothesis of the disease. Mutations in glucose transporters, notably those identified in GLUT1 deficiency syndrome, and some recreational drug compounds also alter the expression and/or activity of glucose transporters at the blood-brain barrier. Approaches for drug delivery across the blood-brain barrier include the pro-drug strategy whereby drug molecules are conjugated to glucose transporter substrates or encapsulated in nano-enabled delivery systems (e.g. liposomes, micelles, nanoparticles) that are functionalised to target glucose transporters. Finally, the continuous development of blood-brain barrier in vitro models is important for studying glucose transporter function, effects of disease conditions and interactions with drugs and xenobiotics.
Similar content being viewed by others
References
Nicholson C (2001) Diffusion and related transport mechanisms in brain tissue. Rep Prog Phys 64(7):815–884
Avdeef A (2001) Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1(4):277–351
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1–3):3–26
Hawkins RA, O'Kane RL, Simpson IA, Viña JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136(1):218S–226S
Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178–201
Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31(4):497–511
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1):13–25
Redzic Z (2011) Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8(1):3
Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC (2013) The blood-brain barrier: an engineering perspective. Front Neuroeng 6:7
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT (2014) Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des 20(10):1422–1449
Keaney J, Campbell M (2015) The dynamic blood-brain barrier. FEBS J 282(21):4067–4079
Enerson BE, Drewes LR (2006) The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab 26(7):959–973
Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A (2000) Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm Res 17(1):55–62
Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8(1):16–30
Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12):723–738
Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32(11):1959–1972
Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther 136(1):82–93
Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, Luk W, Lu Y et al (2014) Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med 211(2):233–244
Strazielle N, Ghersi-Egea JF (2015) Efflux transporters in blood-brain interfaces of the develo** brain. Front Neurosci 9:21
Wittmann G, Szabon J, Mohácsik P, Nouriel SS, Gereben B, Fekete C, Lechan RM (2015) Parallel regulation of thyroid hormone transporters OATP1c1 and MCT8 during and after endotoxemia at the blood-brain barrier of male rodents. Endocrinology 156(4):1552–1564
Kuzawa CW, Chugani HT, Grossman LI, Lipovich L, Muzik O, Hof PR, Wildman DE, Sherwood CC et al (2014) Metabolic costs and evolutionary implications of human brain development. Proc Natl Acad Sci U S A 111(36):13010–13015
Benarroch EE (2014) Brain glucose transporters: implications for neurologic disease. Neurology 82(15):1374–1379
Dick APK, Harik SI, Klip A, Walker DM (1984) Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc Natl Acad Sci U S A 81(22):7233–7237
Joost HG, Thorens B (2001) The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 18(4):247–256
Uldry M, Thorens B (2004) The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch 447(5):480–489
Zhao FQ, Keating AF (2007) Functional properties and genomics of glucose transporters. Curr Genomics 8(2):113–128
Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C (2007) Facilitated hexose transporters: new perspectives on form and function. Physiology (Bethesda) 22:234–240
Carruthers A, DeZutter J, Ganguly A, Devaskar SU (2009) Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab 297(4):E836–E848
Augustin R (2010) The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life 62(5):315–333
Thorens B, Mueckler M (2010) Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 298(2):E141–E145
Cura AJ, Carruthers A (2012) Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis. Compr Physiol 2(2):863–914
Mueckler M, Thorens B (2013) The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34(2–3):121–138
Madej MG, Sun L, Yan N, Kaback HR (2014) Functional architecture of MFS D-glucose transporters. Proc Natl Acad Sci U S A 111(7):E719–E727
Pao SS, Paulsen IT, Saier MH Jr (1998) Major facilitator superfamily. Microbiol Mol Biol Rev 62(1):1–34
Saier MH Jr, Beatty JT, Goffeau A, Harley KT, Heijne WH, Huang SC, Jack DL, Jähn PS et al (1999) The major facilitator superfamily. J Mol Microbiol Biotechnol 1(2):257–279
Reddy VS, Shlykov MA, Castillo R, Sun EI, Saier MH Jr (2012) The major facilitator superfamily (MFS) revisited. FEBS J 279(111):2022–2035
Iancu CV, Zamoon J, Woo SB, Aleshin A, Choe JY (2013) Crystal structure of a glucose/H+ symporter and its mechanism of action. Proc Natl Acad Sci U S A 110(44):17862–17867
Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91(2):733–794
Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Asp Med 34(2–3):183–196
Kasahara M, Hinkle PC (1997) Reconstitution and purification of the D-glucose transporter from human erythrocytes. J Biol Chem 252(20):7384–7390
Zoccoli MA, Baldwin SA, Lienhard GE (1978) The monosaccharide transport system of the human erythrocyte. Solubilization and characterization on the basis of cytochalasin B binding. J Biol Chem 253(19):6923–6930
Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, Allard WJ, Lienhard GE et al (1985) Sequence and structure of a human glucose transporter. Science 229(4717):941–945
Baldwin SA, Lienhard GE (1989) Purification and reconstitution of glucose transporter from human erythrocytes. Methods Enzymol 174:39–50
Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, Yan N (2014) Crystal structure of the human glucose transporter GLUT1. Nature 510(7503):121–125
Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, Yan N (2012) Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature 490(7420):361–366
Barnett JE, Holman GD, Munday KA (1973) Structural requirements for binding to the sugar transport system of the human erythrocyte. Biochem J 131(2):211–221
Leitch JM, Carruthers A (2009) Alpha- and beta-monosaccharide transport in human erythrocytes. Am J Physiol Cell Physiol 296(1):C151–C161
Lowe AG, Walmsley AR (1986) The kinetics of glucose transport in human red blood cells. Biochim Biophys Acta 857(2):146–154
Wheeler TJ, Hinkle PC (1981) Kinetic properties of the reconstituted glucose transporter from human erythrocytes. J Biol Chem 256(17):8907–8914
Wheeler TJ, Cole D, Hauck MA (1998) Characterization of glucose transport activity reconstituted from heart and other tissues. Biochim Biophys Acta 1414(1–2):217–230
Keller K, Strube M, Mueckler M (1989) Functional expression of the human HepG2 and rat adipocyte glucose transporters in Xenopus oocytes. Comparison of kinetic parameters. J Biol Chem 264(32):18884–18889
Gould GW, Lienhard GE (1989) Expression of a functional glucose transporter in Xenopus oocytes. Biochemistry 28(24):9447–9452
Vera JC, Rosen OM (1989) Functional expression of mammalian glucose transporters in Xenopus laevis oocytes: evidence for cell-dependent insulin sensitivity. Mol Cell Biol 9(10):4187–4195
Nishimura H, Pallardo FV, Seidner GA, Vannucci S, Simpson IA, Birnbaum MJ (1993) Kinetics of GLUT1 and GLUT4 glucose transporters expressed in Xenopus oocytes. J Biol Chem 268(12):8514–8520
Vera JC, Rivas CI, Fischbarg J, Golde DW (1993) Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364(32):79–82
Sage JM, Carruthers A (2014) Human erythrocytes transport dehydroascorbic acid and sugars using the same transporter complex. Am J Physiol Cell Physiol 306(10):C910–C917
KC S, Cárcamo JM, Golde DW (2005) Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J 19(12):1657–1667
Jiang X, McDermott JR, Ajees AA, Rosen BP, Liu Z (2010) Trivalent arsenicals and glucose use different translocation pathways in mammalian GLUT1. Metallomics 2(3):211–219
Patching SG (2015) Roles of facilitative glucose transporter GLUT1 in [18F]FDG positron emission tomography (PET) imaging of human diseases. J Diagn Imaging Ther 2(1):30–102
Bloch R (1973) Inhibition of glucose transport in the human erythrocyte by cytochalasin B. Biochemistry 12(23):4799–4801
Basketter DA, Widdas WF (1978) Asymmetry of the hexose transfer system in human erythrocytes. Comparison of the effects of cytochalasin B, phloretin and maltose as competitive inhibitors. J Physiol 278:389–401
Sergeant S, Kim HD (1985) Inhibition of 3-O-methylglucose transport in human erythrocytes by forskolin. J Biol Chem 260(27):14677–14682
Martin HJ, Kornmann F, Fuhrmann GF (2003) The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chem Biol Interact 146(3):225–235
Robichaud T, Appleyard AN, Herbert RB, Henderson PJ, Carruthers A (2011) Determinants of ligand binding affinity and cooperativity at the GLUT1 endofacial site. Biochemistry 50(15):3137–3148
Farrell CL, Pardridge WM (1991) Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A 88(13):5779–5783
Hawkins RA, Peterson DR, Viña JR (2002) The complementary membranes forming the blood-brain barrier. IUBMB Life 54(3):101–107
Gerhart DZ, LeVasseur RJ, Broderius MA, Drewes LR (1989) Glucose transporter localization in brain using light and electron immunocytochemistry. J Neurosci Res 22(4):464–472
Cornford EM, Hyman S, Swartz BE (1994) The human brain glut1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab 14(1):106–112
Duelli R, Maurer MH, Staudt R, Heiland S, Duembgen L, Kuschinsky W (2000) Increased cerebral glucose utilization and decreased glucose transporter Glut1 during chronic hyperglycemia in rat brain. Brain Res 858(2):338–347
Duelli R, Kuschinsky W (2001) Brain glucose transporters: relationship to local energy demand. News Physiol Sci 16:71–76
McAllister MS, Krizanac-Bengez L, Macchia F, Naftalin RJ, Pedley KC, Mayberg MR, Marroni M, Leaman S et al (2001) Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res 904(1):20–30
Simpson IA, Vannucci SJ, DeJoseph MR, Hawkins RA (2001) Glucose transporter asymmetries in the bovine blood-brain barrier. J Biol Chem 276(16):12725–12729
Cornford EM, Hyman S (2005) Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx 2(1):27–43
Kubo Y, Ohtsuki S, Uchida Y, Terasaki T (2015) Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics. J Pharm Sci 104(9):3060–3068
Devraj K, Klinger ME, Myers RL, Mokashi A, Hawkins RA, Simpson IA (2011) GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res 89(12):1913–1925
Barros LF, Bittner CX, Loaiza A, Porras OH (2007) A quantitative overview of glucose dynamics in the gliovascular unit. Glia 55(12):1222–1237
Kreft M, Lukšič M, Zorec TM, Prebil M, Zorec R (2013) Diffusion of D-glucose measured in the cytosol of a single astrocyte. Cell Mol Life Sci 70(8):1483–1492
Pardridge WM (1983) Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 63(4):1481–1535
Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB (1998) The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure 6(1):39–50
Lund-Andersen H (1979) Transport of glucose from blood to brain. Physiol Rev 59(2):305–352
Blomqvist G, Grill V, Ingvar M, Widén L, Stone-Elander S (1998) The effect of hyperglycaemia on regional cerebral glucose oxidation in humans studied with [1-11C]-D-glucose. Acta Physiol Scand 163(4):403–415
Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Mason GF, Shulman GI, Shulman RG, Tamborlane WV (1992) Direct measurement of brain glucose concentrations in humans by 13C NMR spectroscopy. Proc Natl Acad Sci U S A 89(3):1109–1112
Gruetter R, Ugurbil K, Seaquist ER (1998) Steady-state cerebral glucose concentrations and transport in the human brain. J Neurochem 70(1):397–408
McNay EC, Gold PE (1999) Extracellular glucose concentrations in the rat hippocampus measured by zero-net-flux: effects of microdialysis flow rate, strain, and age. J Neurochem 72(2):785–790
Reinstrup P, Stahl N, Mellergard P, Uski T, Ungerstedt U, Nordstrom CH (2000) Intracerebral microdialysis in clinical practice: baseline values for chemical markers during wakefulness, anesthesia, and neurosurgery. Neurosurgery 47(3):701–709
Wilson JE (1980) Brain hexokinase, the prototype ambiquitous enzyme. Curr Top Cell Regul 16:1–54
McGowan KM, Long SD, Pekala PH (1995) Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 66(3):465–505
Dwyer KJ, Boado RJ, Pardridge WM (1996) Cis-element/cytoplasmic protein interaction within the 3'-untranslated region of the glut1 glucose transporter mRNA. J Neurochem 66(2):449–458
Devaskar S, Zahm DS, Holtzclaw L, Chundu K, Wadzinski BE (1991) Developmental regulation of the distribution of rat brain insulin-insensitive (Glut 1) glucose transporter. Endocrinology 129(3):1530–1540
Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ et al (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42(1):80–89
Zheng PP, Romme E, van der Spek PJ, Dirven CM, Willemsen R, Kros JM (2010) Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann Neurol 68(6):835–844
Vannucci SJ, Seaman LB, Brucklacher RM, Vannucci RC (1994) Glucose transport in develo** rat brain: glucose transporter proteins, rate constants and cerebral glucose utilization. Mol Cell Biochem 140(2):177–184
Nualart F, Godoy A, Reinicke K (1999) Expression of the hexose transporters GLUT1 and GLUT2 during the early development of the human brain. Brain Res 824(1):97–104
Virgintino D, Robertson D, Benagiano V, Errede M, Bertossi M, Ambrosi G, Roncali L (2000) Immunogold cytochemistry of the blood-brain barrier glucose transporter GLUT1 and endogenous albumin in the develo** human brain. Brain Res Dev Brain Res 123(1):95–101
Vannucci SJ, Simpson IA (2003) Developmental switch in brain nutrient transporter expression in the rat. Am J Physiol Endocrinol Metab 285(5):E1127–E1134
Dormire SL (2009) The potential role of glucose transport changes in hot flash physiology: a hypothesis. Biol Res Nurs 10(3):241–247
Morgello S, Uson RR, Schwartz EJ, Haber RS (1995) The human blood-brain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes. Glia 14(1):43–54
Yu S, Ding WG (1998) The 45 kDa form of glucose transporter 1 (glut1) is localized in oligodendrocyte and astrocyte but not in microglia in the rat brain. Brain Res 797(1):65–72
Birnbaum MJ, Haspel HC, Rosen OM (1986) Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci U S A 83(16):5784–5788
Asano T, Takata K, Katagiri H, Ishihara H, Inukai K, Anai M, Hirano H, Yazaki Y et al (1993) The role of N-glycosylation in the targeting and stability of GLUT1 glucose transporter. FEBS Lett 324(3):258–261
Asano T, Katagiri H, Takata K, Lin JL, Ishihara H, Inukai K, Tsukuda K, Kikuchi M et al (1991) The role of N-glycosylation of GLUT1 for glucose transport activity. J Biol Chem 266(36):24632–24636
Onetti R, Baulida J, Bassols A (1997) Increased glucose transport in ras-transformed fibroblasts: a possible role for N-glycosylation of GLUT1. FEBS Lett 407(3):267–270
McMahon RJ, Hwang JB, Frost SC (2000) Glucose deprivation does not affect GLUT1 targeting in 3T3-L1 adipocytes. Biochem Biophys Res Commun 273(3):859–864
Maher F, Vannucci SJ, Simpson IA (1994) Glucose transporter proteins in brain. FASEB J 8(13):1003–1011
Maher F (1995) Immunolocalization of GLUT1 and GLUT3 glucose transporters in primary cultured neurons and glia. J Neurosci Res 42(4):459–469
Maher F, Davies-Hill TM, Lysko PG, Henneberry RC, Simpson IA (1991) Expression of two glucose transporters, GLUT1 and GLUT3, in cultured cerebellar neurons: evidence for neuron-specific expression of GLUT3. Mol Cell Neurosci 2(4):351–360
Mantych GJ, James DE, Chung HD, Devaskar SU (1992) Cellular localization and characterization of glut3 glucose transporter isoform in human brain. Endocrinology 131(3):1270–1278
Gerhart DZ, Broderius MA, Borson ND, Drewes LR (1992) Neurons and microvessels express the brain glucose transporter protein glut3. Proc Natl Acad Sci U S A 89(2):733–737
Maher F, Davies-Hill TM, Simpson IA (1996) Substrate specificity and kinetic parameters of glut3 in rat cerebellar granule neurons. Biochem J 315(3):827–831
Simpson IA, Carruthers A, Vannucci SJ (2007) Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27(11):1766–1791
Maher F, Simpson IA (1994) The GLUT3 glucose transporter is the predominant isoform in primary cultured neurons: assessment by biosynthetic and photoaffinity labelling. Biochem J 301(2):379–384
Vannucci SJ, Maher F, Simpson IA (1997) Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21(1):2–21
Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ (2008) The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrinol Metab 295(2):E242–E253
Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I et al (2013) Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 16(10):1373–1382
Deng D, Sun P, Yan C, Ke M, Jiang X, **ong L, Ren W, Hirata K et al (2015) Molecular basis of ligand recognition and transport by glucose transporters. Nature 526(7573):391–396
Payne J, Maher F, Simpson I, Mattice L, Davies P (1997) Glucose transporter glut 5 expression in microglial cells. Glia 21(3):327–331
Horikoshi Y, Sasaki A, Taguchi N, Maeda M, Tsukagoshi H, Sato K, Yamaguchi H (2003) Human GLUT5 immunolabeling is useful for evaluating microglial status in neuropathological study using paraffin sections. Acta Neuropathol 105(2):157–162
Mantych GJ, James DE, Devaskar SU (1993) Jejunal/kidney glucose transporter isoform (Glut-5) is expressed in the human blood-brain barrier. Endocrinology 132(1):35–40
Burant CF, Takeda J, Brot-Laroche E, Bell GI, Davidson NO (1992) Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 267(21):14523–14526
Kane S, Seatter MJ, Gould GW (1997) Functional studies of human GLUT5: effect of pH on substrate selection and an analysis of substrate interactions. Biochem Biophys Res Commun 238(2):503–505
Douard V, Ferraris RP (2008) Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab 295(2):E227–E237
Barone S, Fussell SL, Singh AK, Lucas F, Xu J, Kim C, Wu X, Yu Y et al (2009) Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem 284(8):5056–5066
Nomura N, Verdon G, Kang HJ, Shimamura T, Nomura Y, Sonoda Y, Hussien SA, Qureshi AA et al (2015) Structure and mechanism of the mammalian fructose transporter GLUT5. Nature 526(7573):397–401
Leloup C, Arluison M, Lepetit N, Cartier N, Marfaing-Jallat P, Ferre P, Penicaud L (1994) Glucose transporter 2 (GLUT 2): expression in specific brain nuclei. Brain Res 638(1–2):221–226
Leloup C, Allard C, Carneiro L, Fioramonti X, Collins S, Pénicaud L (2015) Glucose and hypothalamic astrocytes: more than a fueling role? Neuroscience. doi:10.1016/j.neuroscience.2015.06.007
Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L (2004) Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain–an immunohistochemical study. J Chem Neuroanat 28(3):117–136
Arluison M, Quignon M, Thorens B, Leloup C, Penicaud L (2004) Immunocytochemical localization of the glucose transporter 2 (GLUT2) in the adult rat brain. II. Electron microscopic study. J Chem Neuroanat 28(3):137–146
Jurcovicova J (2014) Glucose transport in brain–effect of inflammation. Endocr Regul 48(1):35–48
Marín-Juez R, Rovira M, Crespo D, van der Vaart M, Spaink HP, Planas JV (2015) GLUT2-mediated glucose uptake and availability are required for embryonic brain development in zebrafish. J Cereb Blood Flow Metab 35(1):74–85
Forsyth R, Fray A, Boutelle M, Fillenz M, Middleditch C, Burchell A (1996) A role for astrocytes in glucose delivery to neurons? Dev Neurosci 18(5–6):360–370
McCall AL, van Bueren AM, Huang L, Stenbit A, Celnik E, Charron MJ (1997) Forebrain endothelium expresses GLUT4, the insulin-responsive glucose transporter. Brain Res 744(2):318–326
Ngarmukos C, Baur EL, Kumagai AK (2001) Co-localization of glut1 and glut4 in the blood-brain barrier of the rat ventromedial hypothalamus. Brain Res 900(1):1–8
Kobayashi M, Nikami H, Morimatsu M, Saito M (1996) Expression and localization of insulin-regulatable glucose transporter (glut4) in rat brain. Neurosci Lett 213(2):103–106
El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Penicaud L, Arluison M (1998) Immunocytochemical localization of the insulin-responsive glucose transporter 4 (glut4) in the rat central nervous system. J Comp Neurol 399(4):492–512
Apelt J, Mehlhorn G, Schliebs R (1999) Insulin-sensitive glut4 glucose transporters are colocalized with glut3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res 57(5):693–705
Reagan LP, Rosell DR, Alves SE, Hoskin EK, McCall AL, Charron MJ, McEwen BS (2002) Glut8 glucose transporter is localized to excitatory and inhibitory neurons in the rat hippocampus. Brain Res 932(1–2):129–134
Sankar R, Thamotharan S, Shin D, Moley KH, Devaskar SU (2002) Insulin-responsive glucose transporters-glut8 and glut4 are expressed in the develo** mammalian brain. Brain Res Mol Brain Res 107(2):157–165
Gomez O, Ballester-Lurbe B, Mesonero JE, Terrado J (2011) Glucose transporters glut4 and glut8 are upregulated after facial nerve axotomy in adult mice. J Anat 219(4):525–530
Schmidt S, Joost HG, Schürmann A (2009) GLUT8, the enigmatic intracellular hexose transporter. Am J Physiol Endocrinol Metab 296(4):E614–E618
Doege H, Bocianski A, Joost HG, Schürmann A (2000) Activity and genomic organization of human glucose transporter 9 (GLUT9), a novel member of the family of sugar-transport facilitators predominantly expressed in brain and leucocytes. Biochem J 350(3):771–776
Stuart CA, Ross IR, Howell ME, McCurry MP, Wood TG, Ceci JD, Kennel SJ, Wall J (2011) Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Res 1384:15–22
Nishizaki T, Kammesheidt A, Sumikawa K, Asada T, Okada Y (1995) A sodium- and energy-dependent glucose transporter with similarities to sglt1-2 is expressed in bovine cortical vessels. Neurosci Res 22(1):13–22
Nishizaki T, Matsuoka T (1998) Low glucose enhances Na+/glucose transport in bovine brain artery endothelial cells. Stroke 29(4):844–849
Elfeber K, Köhler A, Lutzenburg M, Osswald C, Galla HJ, Witte OW, Koepsell H (2004) Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem Cell Biol 121(3):201–207
Vemula S, Roder KE, Yang T, Bhat GJ, Thekkumkara TJ, Abbruscato TJ (2009) A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther 328(2):487–495
Poppe R, Karbach U, Gambaryan S, Wiesinger H, Lutzenburg M, Kraemer M, Witte OW, Koepsell H (1997) Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem 69(1):84–94
O'Malley D, Reimann F, Simpson AK, Gribble FM (2006) Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes 55(12):3381–3386
Yu AS, Hirayama BA, Timbol G, Liu J, Diez-Sampedro A, Kepe V, Satyamurthy N, Huang SC et al (2013) Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol 304(3):C240–C247
Wright EM, Hirayama BA, Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261(1):32–43
Chen XZ, Coady MJ, Jackson F, Berteloot A, Lapointe JY (1995) Thermodynamic determination of the Na+: glucose coupling ratio for the human SGLT1 cotransporter. Biophys J 69(6):2405–2414
Mackenzie B, Loo DD, Wright EM (1998) Relationships between Na+/glucose cotransporter (SGLT1) currents and fluxes. J Membr Biol 162(2):101–106
Lee WJ, Peterson DR, Sukowski EJ, Hawkins RA (1997) Glucose transport by isolated plasma membranes of the bovine blood-brain barrier. Am J Physiol 272(5):C1552–C1557
Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93(1):397–404
You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK et al (1995) Molecular characteristics of Na+-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270(49):29365–29371
Yu AS, Hirayama BA, Timbol G, Liu J, Basarah E, Kepe V, Satyamurthy N, Huang SC et al (2010) Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol 299(6):C1277–C1284
Kumagai AK, Kang YS, Boado RJ, Pardridge WM (1995) Upregulation of bloodbrain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 44(12):1399–1404
Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher F, Koehler-Stec EM, Vannucci SJ et al (1999) Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem 72(1):238–247
Sajja RK, Prasad S, Cucullo L (2014) Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line. Fluids Barriers CNS 11:8
Uehara Y, Nipper V, McCall AL (1997) Chronic insulin hypoglycemia induces GLUT-3 protein in rat brain neurons. Am J Physiol 272(4):E716–E719
Lee DH, Chung MY, Lee JU, Kang DG, Paek YW (2000) Changes of glucose transporters in the cerebral adaptation to hypoglycemia. Diabetes Res Clin Pract 47(1):15–23
Sahin K, Tuzcu M, Orhan C, Ali S, Sahin N, Gencoglu H, Ozkan Y, Hayirli A et al (2013) Chromium modulates expressions of neuronal plasticity markers and glial fibrillary acidic proteins in hypoglycemia-induced brain injury. Life Sci 93(25–26):1039–1048
Zhao F, Deng J, Yu X, Li D, Shi H, Zhao Y (2015) Protective effects of vascular endothelial growth factor in cultured brain endothelial cells against hypoglycemia. Metab Brain Dis 30(4):999–1007
(2012) Standards of medical care in diabetes. Diabetes Care 35(1):S11–S63
Pardridge WM, Triguero D, Farrell CR (1990) Downregulation of blood-brain barrier glucose transporter in experimental diabetes. Diabetes 39(9):1040–1044
Hou WK, **an YX, Zhang L, Lai H, Hou XG, Xu YX, Yu T, Xu FY et al (2007) Influence of blood glucose on the expression of glucose trans-porter proteins 1 and 3 in the brain of diabetic rats. Chin Med J (Engl) 120(19):1704–1709
Hasselbalch SG, Knudsen GM, Capaldo B, Postiglione A, Paulson OB (2001) Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. J Clin Endocrinol Metab 86(5):1986–1990
Jacob RJ, Fan X, Evans ML, Dziura J, Sherwin RS (2002) Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: no evidence for protective adaptation by the blood brain barrier. Metabolism 51(12):1522–1524
Seaquist ER, Tkac I, Damberg G, Thomas W, Gruetter R (2005) Brain glucose concentrations in poorly controlled diabetes mellitus as measured by high-field magnetic resonance spectroscopy. Metabolism 54(8):1008–1013
www.alz.org/downloads/ facts_Fig.s_2012.pdf
Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64(4):570–575
Iadecola C, Davisson RL (2008) Hypertension and cerebrovascular dysfunction. Cell Metab 7(6):476–484
Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71(14):1057–1064
Knopman DS, Roberts R (2010) Vascular risk factors: imaging and neuropathologic correlates. J Alzheimers Dis 20(3):699–709
Naderali EK, Ratcliffe SH, Dale MC (2009) Obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen 24(6):445–449
Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, O’brien RJ (2010) Atherosclerosis, dementia, and Alzheimer’s disease in the BLSA cohort. Ann Neurol 68(2):231–240
Suemoto CK, Nitrini R, Grinberg LT, Ferretti RE, Farfel JM, Leite RE, Menezes PR, Fregni F et al (2011) Atherosclerosis and dementia: a cross-sectional study with pathological analysis of the carotid arteries. Stroke 42(12):3614–3615
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698–712
Reitz C (2012) Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012:369808
Armstrong RA (2014) A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol 52(3):211–225
Drachman DA (2014) The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 10(3):372–380
Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun 2:135
Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28(4):202–208
Zlokovic BV (2010) Neurodegeneration and the neurovascular unit. Nat Med 16(12):1370–1371
de la Torre JC (2010) Vascular risk factor detection and control may prevent Alzheimer’s disease. Aging Res Rev 9(3):218–225
Marchesi VT (2011) Alzheimer’s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25(1):5–13
Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2(10):a011452
Lyros E, Bakogiannis C, Liu Y, Fassbender K (2014) Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. Current Alzheimer Res 11(1):18–26
Harik SI, LaManna JC (1991) Altered glucose metabolism in microvessels from patients with Alzheimer’s disease. Ann Neurol 29(5):573
Meneilly GS, Hill A (1993) Alterations in glucose metabolism in patients with Alzheimer’s disease. J Am Geriatr Soc 41(7):710–714
Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA et al (2007) Indices of metabolic dysfunction and oxidative stress. Neurochem Res 32(4–5):717–722
Hunt A, Schonknecht P, Henze M, Seidl U, Haberkorn U, Schroder J (2007) Reduced cerebral glucose metabolism in patients at risk for Alzheimer’s disease. Psychiatry Res 155(2):147–154
Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 1147:180–195
Furst AJ, Lal RA (2011) Amyloid-beta and glucose metabolism in Alzheimer’s disease. J Alzheimers Dis 26(3):105–116
Chen Z, Zhong C (2013) Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108:21–43
Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, Ober BA, Mazoyer BM et al (1989) Regional cerebral glucose transport and utilization in Alzheimer’s disease. Neurology 39(11):1427–1434
Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, Coxson PG, Budinger TF (1991) Diminished glucose transport in Alzheimer’s disease: dynamic pet studies. J Cereb Blood Flow Metab 11(2):323–330
Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE (1996) Diminished glucose transport and phosphorylation in Alzheimer’s disease determined by dynamic FDG-PET. J Nucl Med 37(2):201–208
Samuraki M, Matsunari I, Chen WP, Yajima K, Yanase D, Fujikawa A, Takeda N, Nishimura S et al (2007) Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer’s disease. Eur J Nucl Med Mol Imaging 34(10):1658–1669
Nobili F, Morbelli S (2010) [18F]FDG-PET as a biomarker for early Alzheimer’s disease. Open Nucl Med J 2:46–52
Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20(3):843–854
Mosconi L, McHugh PF (2011) FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging 55(3):250–264
Ishii K (2014) PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol 35(11):2030–2038
Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA, Frisoni G, Caltagirone C (2014) A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int 2014:785039
Shokouhi S, Claassen D, Riddle W (2014) Imaging brain metabolism and pathology in Alzheimer's disease with positron emission tomography. J Alzheimers Dis Parkinsonism 4(2):143
Kalaria RN, Harik SI (1989) Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 53(4):1083–1088
Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of glut1 and glut3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol 35(5):546–551
Harr SD, Simonian NA, Hyman BT (1995) Functional alterations in Alzheimer’s disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol 54(1):38–41
Mooradian AD, Chung HC, Shah GN (1997) Glut-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol Aging 18(5):469–474
Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 26(5):573–578
Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582(2):359–364
Li X, Lu F, Wang JZ, Gong CX (2006) Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 23(8):2078–2086
Dias WB, Hart GW (2007) O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 3(11):766–772
Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132(7):1820–1832
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem 111(1):242–249
Lee CW, Shih YH, Wu SY, Yang T, Lin C, Kuo YM (2013) Hypoglycemia induces tau hyperphosphorylation. Curr Alzheimer Res 10(3):298–308
Yuzwa SA, Vocadlo DJ (2014) O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond. Chem Soc Rev 43(19):6839–6858
Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ (2014) The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem 289(50):34472–34481
Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, Sengillo JD, Hillman S et al (2015) GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 18(4):521–530
Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol 71(3):365–376
Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441:64–78
Adeghate E, Donáth T, Adem A (2013) Alzheimer disease and diabetes mellitus: do they have anything in common? Curr Alzheimer Res 10(6):609–617
Ahmad W (2013) Overlapped metabolic and therapeutic links between Alzheimer and diabetes. Mol Neurobiol 47(1):399–424
De Felice FG (2013) Connecting type 2 diabetes to Alzheimer's disease. Expert Rev Neurother 13(12):1297–1299
Jayaraman A, Pike CJ (2014) Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep 14(4):476
Mushtaq G, Khan JA, Kamal MA (2014) Biological mechanisms linking Alzheimer's disease and type-2 diabetes mellitus. CNS Neurol Disord Drug Targets 13(7):1192–1201
Verdile G, Fuller SJ, Martins RN (2015) The role of type 2 diabetes in neurodegeneration. Neurobiol Dis. doi:10.1016/j.nbd.2015.04.008
de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2(6):1101–1113
Kroner Z (2009) The relationship between Alzheimer’s disease and diabetes: type 3 diabetes? Altern Med Rev 14(4):373–379
Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G (2012) Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 15(2):217–221
Ahmed S, Mahmood Z, Zahid S (2015) Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci 36(10):1763–1769
Shah K, Desilva S, Abbruscato T (2012) The role of glucose transporters in brain disease: diabetes and Alzheimer’s disease. Int J Mol Sci 13(10):12629–12655
Thompson BJ, Ronaldson PT (2014) Drug delivery to the ischemic brain. Adv Pharmacol 71:165–202
Shah K, Abbruscato T (2014) The role of blood-brain barrier transporters in pathophysiology and pharmacotherapy of stroke. Curr Pharm Des 20(10):1510–1522
Alluri H, Anasooya Shaji C, Davis ML, Tharakan B (2015) Oxygen-glucose deprivation and reoxygenation as an in vitro ischemia-reperfusion injury model for studying blood-brain barrier dysfunction. J Vis Exp 99:e52699
McCall AL, Van Bueren AM, Nipper V, Moholt-Siebert M, Downes H, Lessov N (1996) Forebrain ischemia increases GLUT1 protein in brain microvessels and parenchyma. J Cereb Blood Flow Metab 16(1):69–76
Vannucci SJ, Seaman LB, Vannucci RC (1996) Effects of hypoxia-ischemia on GLUT1 and GLUT3 glucose transporters in immature rat brain. J Cereb Blood Flow Metab 16(1):77–81
Vannucci SJ, Reinhart R, Maher F, Bondy CA, Lee WH, Vannucci RC, Simpson IA (1998) Alterations in GLUT1 and GLUT3 glucose transporter gene expression following unilateral hypoxia-ischemia in the immature rat brain. Brain Res Dev Brain Res 107(2):255–264
Yeh WL, Lin CJ, Fu WM (2008) Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol Pharmacol 73(1):170–177
Cura AJ, Carruthers A (2010) Acute modulation of sugar transport in brain capillary endothelial cell cultures during activation of the metabolic stress pathway. J Biol Chem 285(20):15430–15439
Zhang WW, Zhang L, Hou WK, Xu YX, Xu H, Lou FC, Zhang Y, Wang Q (2009) Dynamic expression of glucose transporters 1 and 3 in the brain of diabetic rats with cerebral ischemia reperfusion. Chin Med J (Engl) 122(17):1996–2001
Zovein A, Flowers-Ziegler J, Thamotharan S, Shin D, Sankar R, Nguyen K, Gambhir S, Devaskar SU (2004) Postnatal hypoxic-ischemic brain injury alters mechanisms mediating neuronal glucose transport. Am J Physiol Regul Integr Comp Physiol 286(2):R273–R282
Iwabuchi S, Kawahara K (2011) Inducible astrocytic glucose transporter-3 contributes to the enhanced storage of intracellular glycogen during reperfusion after ischemia. Neurochem Int 59(2):319–325
Espinoza-Rojo M, Iturralde-Rodríguez KI, Chánez-Cárdenas ME, Ruiz-Tachiquín ME, Aguilera P (2010) Glucose transporters regulation on ischemic brain: possible role as therapeutic target. Cent Nerv Syst Agents Med Chem 10(4):317–325
Zhang S, Zuo W, Guo XF, He WB, Chen NH (2014) Cerebral glucose transporter: the possible therapeutic target for ischemic stroke. Neurochem Int 70:22–29
Shah KK, Boreddy PR, Abbruscato TJ (2015) Nicotine pre-exposure reduces stroke-induced glucose transporter-1 activity at the blood-brain barrier in mice. Fluids Barriers CNS 12:10
Yamazaki Y, Harada S, Tokuyama S (2012) Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Res 1489:113–120
Yamazaki Y, Harada S, Tokuyama S (2014) Sodium-glucose transporter type 3-mediated neuroprotective effect of acetylcholine suppresses the development of cerebral ischemic neuronal damage. Neuroscience 269:134–142
Yamazaki Y, Harada S, Tokuyama S (2015) Relationship between cerebral sodium-glucose transporter and hyperglycemia in cerebral ischemia. Neurosci Lett 604:134–139
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI (1991) Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. New Eng J Med 325(10):703–709
Klepper J, Willemsen M, Verrips A, Guertsen E, Herrmann R, Kutzick C, Flörcken A, Voit T (2001) Autosomal dominant transmission of GLUT1 deficiency. Hum Mol Genet 10(1):63–68
Klepper J, Scheffer H, Elsaid MF, Kamsteeg EJ, Leferink M, Ben-Omran T (2009) Autosomal recessive inheritance of GLUT1 deficiency syndrome. Neuropediatrics 40(5):207–210
Rotstein M, Engelstad K, Yang H, Wang D, Levy B, Chung WK, De Vivo DC (2010) Glut1 deficiency: inheritance pattern determined by haploinsufficiency. Ann Neurol 68(6):955–958
Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE (2000) Immunohistochemical staining of GLUT1 in benign, hyperplastic and malignant endometrial epithelia. Cancer 88(12):2774–2781
Klepper J, Leiendecker B, Bredahl R, Athanassopoulos S, Heinen F, Gertsen E, Flörcken A, Metz A et al (2002) Introduction of a ketogenic diet in young infants. J Inherit Metab Dis 25(6):449–460
Brockmann K (2009) The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev 31(7):545–552
De Giorgis V, Veggiotti P (2013) GLUT1 deficiency syndrome 2013: current state of the art. Seizure 22(10):803–811
Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC (2013) Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep 13(4):342
Gras D, Roze E, Caillet S, Méneret A, Doummar D, Billette de Villemeur T, Vidailhet M, Mochel F (2014) GLUT1 deficiency syndrome: an update. Rev Neurol (Paris) 170(2):91–99
Leen WG, Taher M, Verbeek MM, Kamsteeg EJ, van de Warrenburg BP, Willemsen MA (2014) GLUT1 deficiency syndrome into adulthood: a follow-up study. J Neurol 261(3):589–599
Ragona F, Matricardi S, Castellotti B, Patrini M, Freri E, Binelli S, Granata T (2014) Refractory absence epilepsy and glut1 deficiency syndrome: a new case report and literature review. Neuropediatrics 45(5):328–332
Tzadok M, Nissenkorn A, Porper K, Matot I, Marcu S, Anikster Y, Menascu S, Bercovich D et al (2014) The many faces of Glut1 deficiency syndrome. J Child Neurol 29(3):349–359
Suls A, Mullen SA, Weber YG, Verhaert K, Ceulemans B, Guerrini R, Wuttke TV, Salvo-Vargas A et al (2009) Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol 66(3):415–419
Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE (2010) Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology 75(5):432–440
Arsov T, Mullen SA, Damiano JA, Lawrence KM, Huh LL, Nolan M, Young H, Thouin A et al (2012) Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency. Epilepsia 53(12):e204–e207
Arsov T, Mullen SA, Rogers S, Phillips AM, Lawrence KM, Damiano JA, Goldberg-Stern H, Afawi Z et al (2012) Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann Neurol 72(5):807–815
Striano P, Weber YG, Toliat MR, Schubert J, Leu C, Chaimana R, Baulac S, Guerrero R et al (2012) GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology 78(8):557–562
Weber YG, Storch A, Wuttke TV, Brockmann K, Kempfle J, Maljevic S, Margari L, Kamm C et al (2008) GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 118(6):2157–2168
Suls A, Dedeken P, Goffin K, Van Esch H, Dupont P, Cassiman D, Kempfle J, Wuttke TV et al (2008) Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 131(7):1831–1844
Schneider SA, Paisan-Ruiz C, Garcia-Gorostiaga I, Quinn NP, Weber YG, Lerche H, Hardy J, Bhatia KP (2009) GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord 24(11):1684–1688
Weber YG, Kamm C, Suls A, Kempfle J, Kotschet K, Schüle R, Wuttke TV, Maljevic S et al (2011) Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology 77(10):959–964
Verrotti A, D'Egidio C, Agostinelli S, Gobbi G (2012) Glut1 deficiency: when to suspect and how to diagnose? Eur J Paediatr Neurol 16(1):3–9
Leen WG, Wevers RA, Kamsteeg EJ, Scheffer H, Verbeek MM, Willemsen MA (2013) Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA Neurol 70(11):1440–1444
Klepper J, Garcia-Alvarez M, O'Driscoll KR, Parides MK, Wang D, Ho YY, De Vivo DC (1999) Erythrocyte 3-O-methyl-D-glucose uptake assay for diagnosis of glucose-transporter-protein syndrome. J Clin Lab Anal 13(3):116–121
Yang H, Wang D, Engelstad K, Bagay L, Wei Y, Rotstein M, Aggarwal V, Levy B et al (2011) Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 70(6):996–1005
Wang D, Pascual JM, De Vivo D. Glucose transporter type 1 deficiency syndrome. In Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K (eds). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2015
Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC (2002) Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol 52(4):458–464
Klepper J, Diefenbach S, Kohlschütter A, Voit T (2004) Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins Leukot Essent Fatty Acids 70(3):321–327
Klepper J (2008) Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia 49(8):46–49
Klepper J, Leiendecker B (2013) Glut1 deficiency syndrome and novel ketogenic diets. J Child Neurol 28(8):1045–1048
Bertoli S, Trentani C, Ferraris C, De Giorgis V, Veggiotti P, Tagliabue A (2014) Long-term effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: a case series. Nutrition 30(6):726–728
Veggiotti P, De Giorgis V (2014) Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. Curr Treat Options Neurol 16(5):291
Chenouard A, Vuillaumier-Barrot S, Seta N, Kuster A (2015) A cause of permanent ketosis: GLUT-1 deficiency. JIMD Rep 18:79–83
Singh LD, Singh SP, Handa RK, Ehmann S, Snyder AK (1996) Effects of ethanol on GLUT1 protein and gene expression in rat astrocytes. Metab Brain Dis 11(4):343–357
Hu IC, Singh SP, Snyder AK (1995) Effects of ethanol on glucose transporter expression in cultured hippocampal neurons. Alcohol Clin Exp Res 19(6):1398–1402
Handa RK, DeJoseph MR, Singh LD, Hawkins RA, Singh SP (2000) Glucose transporters and glucose utilization in rat brain after acute ethanol administration. Metab Brain Dis 15(3):211–222
Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J (2011) Inhibitory effects of alcohol on glucose transport across the blood-brain barrier leads to neurodegeneration: preventive role of acetyl-L-carnitine. Psychopharmacology (Berlin) 214(3):707–718
Duelli R, Staudt R, Grünwald F, Kuschinsky W (1998) Increase of glucose transporter densities (Glut1 and Glut3) during chronic administration of nicotine in rat brain. Brain Res 782(1–2):36–42
Canis M, Mack B, Gires O, Maurer MH, Kuschinsky W, Duembgen L, Duelli R (2009) Increased densities of monocarboxylate transport protein MCT1 after chronic administration of nicotine in rat brain. Neurosci Res 64(4):429–435
Abdul Muneer PM, Alikunju S, Szlachetka AM, Murrin LC, Haorah J (2011) Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol Neurodegener 6:23
Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J (2011) Methamphetamine inhibits the glucose uptake by human neurons and astrocytes: stabilization by acetyl-L-carnitine. PLoS One 6(4):e19258
Rask-Andersen M, Masuram S, Fredriksson R, Schiöth HB (2013) Solute carriers as drug targets: current use, clinical trials and prospective. Mol Asp Med 34(2–3):702–710
Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3(2):90–105
Pardridge WM (2005) Molecular biology of the blood-brain barrier. Mol Biotechnol 30(1):57–70
Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12(1–2):54–61
Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24(9):1745–1758
Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF (2009) Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23(1):35–58
Stenehjem DD, Hartz AM, Bauer B, Anderson GW (2009) Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med Chem 1(9):1623–1641
Ronaldson PT (2014) Targeting transporters for CNS drug delivery. Curr Pharm Des 20(10):1419–1421
Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D (2014) Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine 9:795–811
On NH, Miller DW (2014) Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier. Curr Pharm Des 20(10):1499–1509
Tashima T (2015) Intriguing possibilities and beneficial aspects of transporter-conscious drug design. Bioorg Med Chem 23(15):4119–4131
Pardridge WM (2015) Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opin Ther Targets 19(8):1059–1072
Yang C, Tirucherai GS, Mitra AK (2001) Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin Biol Ther 1(2):159–175
Prokai-Tatrai K, Prokai L (2003) Modifying peptide properties by prodrug design for enhanced transport into the CNS. Prog Drug Res 61:155–188
Stella VJ, Nti-Addae KW (2007) Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59(7):677–694
Huttunen KM, Rautio J (2011) Prodrugs–an efficient way to breach delivery and targeting barriers. Curr Top Med Chem 11(18):2265–2287
Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S (2008) Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13(5):1035–1065
Pavan B, Dalpiaz A (2011) Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system? Curr Pharm Des 17(32):3560–3576
Peura L, Malmioja K, Huttunen K, Leppänen J, Hämäläinen M, Forsberg MM, Gynther M, Rautio J et al (2013) Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. Pharm Res 30(10):2523–2537
Tamai I, Tsuji A (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89(11):1371–1388
Guo X, Geng M, Du G (2005) Glucose transporter 1, distribution in the brain and in neural disorders: its relationship with transport of neuroactive drugs through the blood-brain barrier. Biochem Genet 43(3–4):175–187
Halmos T, Santarromana M, Antonakis K, Scherman D (1996) Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol 318(2–3):477–484
Halmos T, Santarromana M, Antonakis K, Scherman D (1997) Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohydr Res 299(1–2):15–21
Bilsky EJ, Egleton RD, Mitchell SA, Palian MM, Davis P, Huber JD, Jones H, Yamamura HI et al (2000) Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem 43(13):2586–2590
Polt R, Porreca F, Szabò LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Harvath R et al (1994) Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A 91(15):7114–7118
Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M et al (2004) Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J Pharmacol Exp Ther 311(1):290–297
Battaglia G, La Russa M, Bruno V, Arenare L, Ippolito R, Copani A, Bonina F, Nicoletti F (2000) Systematically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res 860(1–2):149–156
Bonina F, Arenare L, Ippolito R, Boatto G, Battaglia G, Bruno V, de Caparariis P (2000) Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int J Pharm 202(1–2):79–88
Bonina F, Puglia C, Rimoli MG, Melisi D, Boatto G, Nieddu M, Malignano A, La Rana G et al (2003) Glycosyl derivatives of dopamine and L-dopa as antiparkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target 11(1):25–36
Dalpiaz A, Filosa R, de Caprariis P, Conte G, Bortolotti F, Biondi C, Scatturin A, Prasad PD et al (2007) Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. Int J Pharm 336(1):133–139
Gynther M, Ropponen J, Laine K, Leppänen J, Haapakoski P, Peura L, Järvinen T, Rautio J (2009) Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem 52(10):3348–3353
Chen Q, Gong T, Liu J, Wang X, Fu H, Zhang Z (2009) Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 17(4):318–328
Zhao Y, Qu B, Wu X, Li X, Liu Q, ** X, Guo L, Hai L et al (2014) Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with "lock-in" function. Eur J Med Chem 82:314–323
Jain KK (2012) Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (London) 7(8):1225–1233
Costantino L, Boraschi D, Eaton M (2014) Challenges in the design of clinically useful brain-targeted drug nanocarriers. Curr Med Chem 21(37):4227–4246
Zhou X, Porter AL, Robinson DK, Shim MS, Guo Y (2014) Nano-enabled drug delivery: a research profile. Nanomedicine 10(5):889–896
Hwang SR, Kim K (2014) Nano-enabled delivery systems across the blood-brain barrier. Arch Pharm Res 37(1):24–30
Ma J, Porter AL, Aminabhavi TM, Zhu D (2015) Nano-enabled drug delivery systems for brain cancer and Alzheimer's disease: research patterns and opportunities. Nanomedicine 11(7):1763–1771
Qin Y, Fan W, Chen H, Yao N, Tang W, Tang J, Yuan W, Kuai R et al (2010) In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 18(7):536–549
Lei F, Fan W, Li XK, Wang S, Hai L, Wu Y (2011) Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes. Chin Chem Lett 22(7):831–834
**e F, Yao N, Qin Y, Zhang Q, Chen H, Yuan M, Tang J, Li X et al (2012) Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting. Int J Nanomedicine 7:163–175
Qu B, Li X, Guan M, Li X, Hai L, Wu Y (2014) Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes. Eur J Med Chem 72:110–118
Hao ZF, Cui YX, Li MH, Du D, Liu MF, Tao HQ, Li S, Cao FY et al (2013) Liposomes modified with P-aminophenyl-α-D-mannopyranoside: a carrier for targeting cerebral functional regions in mice. Eur J Pharm Biopharm 84(3):505–516
Du D, Chang N, Sun S, Li M, Yu H, Liu M, Liu X, Wang G et al (2014) The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain. J Control Release 182:99–110
Zidan AS, Aldawsari H (2015) Ultrasound effects on brain-targeting mannosylated liposomes: in vitro and blood-brain barrier transport investigations. Drug Des Devel Ther 9:3885–3898
Shao K, Zhang Y, Ding N, Huang S, Wu J, Li J, Yang C, Leng Q et al (2015) Functionalized nanoscale micelles with brain targeting ability and intercellular microenvironment biosensitivity for anti-intracranial infection applications. Adv Healthc Mater 4(2):291–300
Shao K, Ding N, Huang S, Ren S, Zhang Y, Kuang Y, Guo Y, Ma H et al (2014) Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. ACS Nano 8(2):1191–1203
Guo Y, Zhang Y, Li J, Zhang Y, Lu Y, Jiang X, He X, Ma H et al (2015) Cell microenvironment-controlled antitumor drug releasing-nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy. ACS Appl Mater Interfaces 7(9):5444–5453
Niu J, Wang A, Ke Z, Zheng Z (2014) Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating. J Drug Target 22(8):712–723
Gromnicova R, Davies HA, Sreekanthreddy P, Romero IA, Lund T, Roitt IM, Phillips J, Male DK (2013) Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One 8(12):e81043
Jiang X, **n H, Ren Q, Gu J, Zhu L, Du F, Feng C, **e Y et al (2014) Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 35(1):518–529
Naik P, Cucullo L (2012) In vitro blood-brain barrier models: current and perspective technologies. J Pharm Sci 101(4):1337–1354
Abbott NJ (2002) Astrocyte‐endothelial interactions and the blood‐brain barrier permeability. J Anat 200(6):629–638
Parkinson FE, Hacking C (2005) Pericyte abundance affects sucrose permeability in cultures of rat brain microvascular endothelial cells. Brain Res 1049(1):8–14
He Y, Yao Y, Tsirka SE, Cao Y (2014) Cell-culture models of the blood-brain barrier. Stroke 45(8):2514–2526
Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A et al (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19(13):1872–1874
Tarbell JM (2010) Shear stress and the endothelial transport barrier. Cardiovasc Res 87(2):320–330
Bussolari SR, Dewey CF Jr, Gimbrone MA Jr (1982) Apparatus for subjecting living cells to fluid shear stress. Rev Sci Instrum 53(12):1851–1854
Stanness KA, Guatteo E, Janigro D (1996) A dynamic model of the blood-brain barrier “in vitro”. Neurotoxicology 17(2):481–496
Janigro D, Leaman SM, Stanness KA (1999) Dynamic modeling of the blood-brain barrier: a novel tool for studies of drug delivery to the brain. Pharm Sci Technol Today 2(1):7–12
Cucullo L, McAllister MS, Kight K, Krizanac-Bengez L, Marroni M, Mayberg MR, Stanness KA, Janigro D (2002) A new dynamic in vitro model for the multidimensional study of astrocyte-endothelial cell interactions at the blood-brain barrier. Brain Res 951(2):243–254
Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L (2006) Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res 1109(1):1–13
Cucullo L, Couraud PO, Weksler B, Romero IA, Hossain M, Rapp E, Janigro D (2008) Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab 28(2):312–328
Booth R, Kim H (2011) A multi-layered microfluidic device for in vitro bloodbrain barrier permeability studies. In: International conference on miniaturized systems for chemistry and life sciences. Red Hook: Curran Associates, Inc. pp 1388–1390
Booth R, Kim H (2012) Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). Lab Chip 12(10):1784–1792
Yeon JH, Na D, Choi K, Ryu SW, Choi C, Park JK (2012) Reliable permeability assay system in a microfluidic device mimicking cerebral vasculatures. Biomed Microdevices 14(6):1141–1148
Griep LM, Wolbers F, de Wagenaar B, ter Braak PM, Weksler BB, Romero IA, Couraud PO, Vermes I et al (2013) BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed Microdevices 15(1):145–150
Prabhakarpandian B, Shen MC, Nichols JB, Mills IR, Sidoryk-Wegrzynowicz M, Aschner M, Pant K (2013) SyM-BBB: a microfluidic blood brain barrier model. Lab Chip 13(6):1093–1101
Gumbleton M, Audus KL (2001) Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 90(11):1681–1698
Deli MA, Abrahám CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 25(1):59–127
Deli E (2007) Blood–brain barrier models (chapter 2). In: Abel L (ed) Handbook of neurochemistry and molecular neurobiology (3rd edition). Springer, Berlin, pp 29–55
Ogunshola OO (2011) In vitro modeling of the blood-brain barrier: simplicity versus complexity. Curr Pharm Des 17(26):2755–2761
Tóth A, Veszelka S, Nakagawa S, Niwa M, Deli MA (2011) Patented in vitro blood-brain barrier models in CNS drug discovery. Recent Pat CNS Drug Discov 6(2):107–118
Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 71(1):113–128
Shawahna R, Decleves X, Scherrmann JM (2013) Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Curr Drug Metab 14(1):120–136
Shityakov S, Salvador E, Förster C (2013) In silico, in vitro and in vivo methods to analyse drug permeation across the blood brain barrier: a critical review. OA Anaesthetics 1:13
Abbott NJ, Dolman DEM, Yusof SR, Reichel A (2014) In vitro models of CNS barriers. In Drug delivery to the brain. New York: Springer pp 163–197
Bicker J, Alves G, Fortuna A, Falcão A (2014) Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur J Pharm Biopharm 87(3):409–432
Czupalla CJ, Liebner S, Devraj K (2014) In vitro models of the blood-brain barrier. Methods Mol Biol 1135:415–437
Palmiotti CA, Prasad S, Naik P, Abul KM, Sajja RK, Achyuta AH, Cucullo L (2014) In vitro cerebrovascular modeling in the 21st century: current and prospective technologies. Pharm Res 31(12):3229–3250
Wilhelm I, Krizbai IA (2014) In vitro models of the blood–brain barrier for the study of drug delivery to the brain. Mol Pharm 11(7):1949–1963
Wolff A, Antfolk M, Brodin B, Tenje M (2015) In vitro blood-brain barrier models–an overview of established models and new microfluidic approaches. J Pharm Sci 104(9):2727–2746
Weksler B, Romero IA, Couraud PO (2013) The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10(1):16
Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J et al (2008) The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem 107(5):1358–1368
Carl SM, Lindley DJ, Das D, Couraud PO, Weksler BB, Romero I, Mowery SA, Knipp GT (2010) ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood-brain barrier cell line, hCMEC/D3 [corrected]. Mol Pharm 7(4):1057–1068
Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10(1):33
Urich E, Lazic SE, Molnos J, Wells I, Freskgård PO (2012) Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 7(5):e38149
Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM et al (2013) Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol Pharm 10(1):289–296
Meireles M, Martel F, Araújo J, Santos-Buelga C, Gonzalez-Manzano S, Dueñas M, de Freitas V, Mateus N et al (2013) Characterization and modulation of glucose uptake in a human blood-brain barrier model. J Membr Biol 246(9):669–677
Lippmann ES, Azarin SM, Kay JE, Nessler RA, Wilson HK, Al-Ahmad A, Palecek SP, Shusta EV (2012) Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol 30(8):783–791
Cecchelli R, Aday S, Sevin E, Almeida C, Culot M, Dehouck L, Coisne C, Engelhardt B et al (2014) A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One 9(6):e99733
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The author declares that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Patching, S.G. Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery. Mol Neurobiol 54, 1046–1077 (2017). https://doi.org/10.1007/s12035-015-9672-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-015-9672-6